Circulation
Articles in this Issue
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation Receiving Oral Antiplatelet Therapy: Definitely Safe, but How Effective?
Letter by Jha Regarding Article, “Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial”
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
BACKGROUND: Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868...
Exercise Intolerance and Response to Training in Patients With Postacute Sequelae of SARS-CoV2 (Long COVID): A Scientific Statement From the American Heart Association
The postacute sequelae of SARS-CoV-2, also known as Long COVID, may affect 10% to 25% of individuals diagnosed with SARS-CoV-2. More than 100 symptoms have been reported among patients with Long COVID...
The Impact of Coronary Artery Disease in Patients With Peripheral Artery Disease Undergoing Lower-Extremity Revascularization for Chronic Limb-Threatening Ischemia
METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy
BACKGROUND: Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism underlying cardiac benefits of exercise in DiaCM remains incompl...
Family Screening in Relatives at Risk for Plakophilin-2–Associated Arrhythmogenic Right Ventricular Cardiomyopathy
BACKGROUND: Penetrance and risk of ventricular arrhythmias (VAs) in arrhythmogenic right ventricular cardiomyopathy (ARVC) are increasingly recognized as bei...
Aortic Aneurysm Risk and the Somatic <i>JAK2</i> <sup> <i>V617F</i> </sup> Mutation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study
BACKGROUND: The somatic JAK2 V617F sequence variation, a key driver of myeloproliferative neoplasms...